SLRN Live signaler | Maksimer profitt med Getagraph.com

KJøP 120583 min ago

@ $7.58

Utstedt: 14 feb 2024 @ 16:18

Avkastning: -39.05%

Forrige signal: feb 13 - 18:30

Forrige signal: Selg

Avkastning: -1.69 %

Live Chart Being Loaded With Signals

Commentary (7 mai 2024 @ 22:00):

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines...

Stats
Dagens volum	1.11M
Gjennomsnittsvolum	1.26M
Markedsverdi	449.71M
EPS	$0 ( 2024-03-26 )
Neste inntjeningsdato	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.910
ATR14	$0.0110 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Lin Shao-lee	Buy	964 829	Employee Stock Option (right to buy)
2024-01-09	Lin Shao-lee	Buy	413 498	Employee Stock Option (right to buy)
2024-01-09	Labrucherie Gil M	Buy	855 513	Employee Stock Option (right to buy)
2024-01-02	Lin Shao-lee	Sell	10 691	Common Stock
2023-12-18	Tetrault Lynn A.	Buy	89 955	Director Stock Option (right to buy)

INSIDER POWER
-1.33
Last 57 transactions
Buy: 28 627 675 \| Sell: 30 925 812

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: -0.82 (strong negative)

Signal:(34.483) Neutral

Acelyrin, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Acelyrin, Inc. Korrelasjon - Valuta/Råvare

0.06
( neutral )

-0.14
( neutral )

0.00
( neutral )

0.04
( neutral )

0.00
( neutral )

-0.38
( neutral )

Acelyrin, Inc. Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-12.25

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-12.25

Financial Reports:

No articles found.

Acelyrin, Inc.

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Sanntidsoppdatering for Acelyrin, Inc. [SLRN]

Upcoming Earnings Alert